Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioCryst to Acquire Astria Therapeutics in $700 Million Deal | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioCryst to Acquire Astria Therapeutics in $700 Million Deal

Adds navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

BioCryst Pharmaceuticals Inc. has agreed to acquire Astria Therapeutics Inc. in a cash-and-stock transaction valued at approximately $700 million, or $13.00 per Astria share. The deal, approved unanimously by both companies’ boards, is expected to close in Q1 2026 pending regulatory and shareholder approvals.

Astria’s lead asset, navenibart, is a long-acting injectable monoclonal antibody in Phase 3 development for hereditary angioedema (HAE) prophylaxis. BioCryst, which markets the oral HAE therapy Orladeyo, aims to leverage its commercial infrastructure to position navenibart as a complementary option for patients preferring infrequent dosing.

The acquisition also includes Astria’s early-stage atopic dermatitis candidate, STAR-0310, for which BioCryst plans to explore strategic alternatives.

Under the terms, Astria shareholders will receive $8.55 in cash and 0.59 BioCryst shares per Astria share, representing a 53% premium over Astria’s October 13 closing price. Post-transaction, Astria shareholders will own roughly 15% of the combined company.

BioCryst has secured a financing facility of up to $550 million from Blackstone to support the deal and recently retired its debt with Pharmakon following the sale of its European business.

Astria CEO Jill Milne will join BioCryst’s board upon closing.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics